
Proteinea is a biotechnology company specializing in the rational engineering of antibody Fc domains using proprietary AI models and computational tools. Their platform enables the design of next-generation antibodies with enhanced efficacy, safety, and convenience by tuning immune function, improving half-life, and targeting biodistribution. Proteinea integrates manufacturability, stability, pharmacokinetics, and delivery considerations into their modular Fc scaffolds to reduce downstream failure and accelerate therapeutic development. Their approach combines AI-driven prediction with lean experimental validation to efficiently translate computational designs into biological reality, positioning them as innovators in biologics engineering for life-threatening diseases.

Proteinea is a biotechnology company specializing in the rational engineering of antibody Fc domains using proprietary AI models and computational tools. Their platform enables the design of next-generation antibodies with enhanced efficacy, safety, and convenience by tuning immune function, improving half-life, and targeting biodistribution. Proteinea integrates manufacturability, stability, pharmacokinetics, and delivery considerations into their modular Fc scaffolds to reduce downstream failure and accelerate therapeutic development. Their approach combines AI-driven prediction with lean experimental validation to efficiently translate computational designs into biological reality, positioning them as innovators in biologics engineering for life-threatening diseases.
Headquarters: Cambridge / Boston, MA
Founded: 2020
Core focus: AI-driven antibody Fc and protein engineering
Total disclosed funding: USD 7,490,000
Notable technologies: RaGene (AI gene/codon optimization)
Biologics engineering—designing next-generation antibodies and sequence optimization to improve therapeutic properties and manufacturability.
2020
Biotechnology
USD 4,700,000
USD 2,200,000
USD 500,000
USD 90,000
“500 Global; Core Vision Investments; Den Venture Capital; ICLUB VC; IndieBio; Jedar Capital; SOSV; Sadu Capital; Sawari Ventures; Shorooq Partners; Sukna Ventures; TA Ventures; UI Investments”
As a Downstream Process Development Lead at Proteinea , you will oversee downstream process development, focusing on protein purification, process optimization, and technology implementation. This role involves leading projects, developing and validating methods, ensuring equipment functionality, and collaborating with cross-functional teams to deliver scalable, high-quality purification processes in a GLP-compliant laboratory environment.
]Hiring Journey Overview We Keep Things Flexible, So Steps Might Sometimes Be Adjusted, Merged, Or Skipped; Here’s What To Expect From Our Hiring Process
You will be invited to visit our office at any point during the process; we always love connecting in person with our potential future team members!
]About Proteinea Proteinea is a pioneering TechBio company that is redefining protein engineering through artificial intelligence and computational biology. Headquartered in Cairo, Egypt, with offices in the USA, Germany, UAE and KSA, we specialize in designing next-generation antibody therapeutics using AI-driven platforms.
Our proprietary technologies, including our industry-leading protein language model, Ankh, enable us to develop precision-engineered biologics faster, at lower costs, and with higher success rates than traditional methods.
At Proteinea , we integrate cutting-edge AI models, proprietary datasets, and state of the art wet-lab validation to accelerate the discovery and development of therapeutic proteins. Our work focuses on engineering antibodies with optimized efficacy, safety, and manufacturability.
Responsibilities
Requirements
Benefits
| Company |
|---|